Evidence map›Paper›PMID 36120957›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Design, synthesis, biological evaluation and molecular docking study of 2,4-diarylimidazoles and 2,4-bis(benzyloxy)-5-arylpyrimidines as novel HSP90 N-terminal inhibitors.

Man Yang, Chenyao Li, Yajing Li, Chen Cheng, Meiyun Shi, Lei Yin, Hongyu Xue, Yajun Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Man YangSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Chenyao LiSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Yajing LiSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Chen ChengSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Meiyun ShiSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Lei YinSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Hongyu XueSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
Yajun LiuSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.ORCID 0000-0002-9539-7279
Dalian University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular chaperone HSP90 plays an essential role in cancer occurrence and development. Therefore, it is an important target for the development of anticancer drugs. 1,3-Dibenzyl-2-aryl imidazolidine (

Indexed as

Antineoplastic AgentsImidazolidinesBenzoquinonesHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicMolecular Docking SimulationProto-Oncogene Proteins c-aktAntineoplastic AgentsBenzoquinonesHSP90 Heat-Shock ProteinsImidazolidinesLactams, MacrocyclicProto-Oncogene Proteins c-akttanespimycin2 4-bis(benzyloxy)-5-arylpyrimidines2 4-diarylimidazolesanticancerHSP90molecular docking

Identifiers

PMID36120957
PMCPMC9518286
OpenAlexW4296330338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.